Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.46 |
| ▸ | BRD2 | P25440 | 8/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 7/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18250005 | 0.90 | BRD4 (0.44) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL18249906 | 0.89 | BRD4 (0.43) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL1905779 | 0.88 | BRD4 (0.58) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL11980662 | 0.85 | BRD4 (0.46) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL1904100 | 0.82 | BRD4 (0.63) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL11980664 | 0.80 | ERN1 (0.47) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL11980659 | 0.79 | CYP3A4 (0.52) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL15980854 | 0.77 | CYP3A4 (0.59) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL18249954 | 0.77 | BRD4 (0.44) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL18249930 | 0.76 | FTO (0.46) | BRD4BRD2BRD3CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133436-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | GLAXOSMITHKLINE LLC | 2015-05-14 | — | — | US | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120208800-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | BRDT, BRD2, BRD4 | BRD4 3/4885BRD2 2/4885BRD3 4/4885 |
| US-20120208800-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | BRD4, BRD3, BRPF3 | BRD4 1/4885BRD2 4/4885BRD3 2/4885 |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | BRD4 2/4885BRD2 5/4885BRD3 6/4885 |
| US-20150133436-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | BRD4, BRD3, BRPF3 | BRD4 1/4885BRD2 4/4885BRD3 2/4885 |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | BRD4 2/4885BRD2 5/4885BRD3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.